BeOne Medicines AG
BeOne Medicines AG Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
2 of 3 strong
The short version
- BeOne Medicines projects 2026 revenue between $6.3 billion and $6.5 billion, raising previous guidance by $100 million. - Strong momentum and growth expected in all markets, supported by continued global expansion. - Modest contributions anticipated from launches of zanidatamab and Sonro during 2026. - U.S. - BeOne Medicines is a growth company focused on sustainable growth with continuous operating leverage (Page 13).
From BeOne Medicines AG's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- BeOne Medicines projects 2026 revenue between $6.3 billion and $6.5 billion, raising previous guidance by $100 million.
- Strong momentum and growth expected in all markets, supported by continued global expansion.
- Modest contributions anticipated from launches of zanidatamab and Sonro during 2026.
- U.S. market shows strong demand growth with relatively stable net pricing.
- Europe demonstrates robust growth (64% increase), with opportunities to further increase BRUKINSA brand share.
- Rest of World markets grew 104%, driven by expansions and launches in key regions such as Japan and Brazil.
2 more points from BeOne Medicines AG's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what BeOne Medicines AG said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The transcript does not explicitly mention current or future capital expenditures (capex) or strategic investments in detail.
- The company is focused on investing to support commercial growth and rapidly advance its innovative pipeline, as indicated by the 16% increase in operating expenses totaling $1.1 billion.
- Investments are primarily driving R&D and SG&A growth, expected to normalize over the year.
- The strategic investment emphasis is on advancing clinical programs, expanding launches (e.g., zanidatamab and Sonro), and strengthening the pipeline through selective external innovation.
2 more points from BeOne Medicines AG's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what BeOne Medicines AG said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from BeOne Medicines AG's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
Arthneeti Pro · Annual
BeOne Medicines AG and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were BeOne Medicines AG Q2 FY26 results?
- BeOne Medicines projects 2026 revenue between $6.3 billion and $6.5 billion, raising previous guidance by $100 million. - Strong momentum and growth expected in all markets, supported by continued global expansion. - Modest contributions anticipated from launches of zanidatamab and Sonro during 2026. - U.S. - BeOne Medicines is a growth company focused on sustainable growth with continuous operating leverage (Page 13).
What is BeOne Medicines AG share price analysis?
BeOne Medicines AG currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 68.6 with a market cap of $32,305. Investors should review the full earnings analysis for detailed insights.
Is BeOne Medicines AG planning capital expenditure?
- The transcript does not explicitly mention current or future capital expenditures (capex) or strategic investments in detail.
Keep BeOne Medicines AG on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.